Boehringer Ingelheim faces allegations that it failed to warn doctors about dangerous side effects of blood-thinning medication Pradaxa in two lawsuits in the Southern District of Florida. Courtesy photo.
Two Florida plaintiffs have filed federal lawsuits against Connecticut-based drug giant Boehringer Ingelheim Pharmaceuticals Inc., accusing it of over-promoting and misrepresenting Pradaxa, a blood-thinning medication that alleges causes internal bleeding.
Pradaxa is used to prevent blood clots and lower the risk of stroke for patients with irregular heartbeats.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
